Genetic causes of hypercalciuric nephrolithiasis

Michael J. Stechman · Nellie Y. Loh · Rajesh V. Thakker

Abstract Renal stone disease (nephrolithiasis) affects 3–5% of the population and is often associated with hypercalciuria. Hypercalciuric nephrolithiasis is a familial disorder in over 35% of patients and may occur as a monogenic disorder that is more likely to manifest itself in childhood. Studies of these monogenic forms of hypercalciuric nephrolithiasis in humans, e.g. Bartter syndrome, Dent’s disease, autosomal dominant hypocalcemic hypercalciuria (ADHH), hypercalciuric nephrolithiasis with hypophosphatemia, and familial hypomagnesemia with hypercalciuria have helped to identify a number of transporters, channels and receptors that are involved in regulating the renal tubular reabsorption of calcium. Thus, Bartter syndrome, an autosomal disease, is caused by mutations of the bumetanide-sensitive Na–K–Cl (NKCC2) co-transporter, the renal outer-medullary potassium (ROMK) channel, the voltage-gated chloride channel, CLC-Kb, the CLC-Kb beta subunit, barttin, or the calcium-sensing receptor (CaSR). Dent’s disease, an X-linked disorder characterized by low molecular weight proteinuria, hypercalciuria and nephrolithiasis, is due to mutations of the chloride/proton antiporter 5, CLC-5; ADHH is associated with activating mutations of the CaSR, which is a G-protein-coupled receptor; hypophosphatemic hypercalciuric nephrolithiasis associated with rickets is due to mutations in the type 2c sodium–phosphate co-transporter (NPT2c); and familial hypomagnesemia with hypercalciuria is due to mutations of paracelmin-1, which is a member of the claudin family of membrane proteins that form the intercellular tight junction barrier in a variety of epithelia. These studies have provided valuable insights into the renal tubular pathways that regulate calcium reabsorption and predispose to hypercalciuria and nephrolithiasis.

Keywords Nephrolithiasis · Nephrocalcinosis · Genetic hypercalciuria · Calcium · Magnesium · Phosphate · Inheritance · Hereditary · Renal tubular disorders

Introduction

Nephrolithiasis (kidney stone disease), which is a common disorder that affects approximately 3–5% of the population [1], is usually associated with a metabolic abnormality that may include hypercalciuria, hyperphosphaturia, hyperoxaluria, hypocitraturia, hyperuricosuria, cystinuria, a low urinary volume and a defect in urinary acidification [2, 3]. If uncorrected, these metabolic abnormalities may lead to recurrent stone formation, whose rate may be as high as 50% at 5 years [4, 5]. The etiology of these metabolic abnormalities and of renal stones is multi-factorial and involves interactions between environmental and genetic determinants [6–8]. The environmental determinants include dietary intake of salt, protein, calcium and other nutrients, fluid intake, urinary tract infections, socio-economic status of the individual, lifestyle and climate [9, 10]. This review will focus on the progress made on the genetic determinants of hypercalciuric nephrolithiasis (Table 1), as these are more likely to present in childhood.

Nephrolithiasis may affect children of all ages, with preponderance for boys [11], but it is important to note that children represent only 2–3% of the total population of stone formers [12]. However, nephrolithiasis is associated with a metabolic abnormality in approximately 50% of
children. The younger child will likely present with hematuria or urinary tract infection due to stones sited predominantly in the kidney, whilst the adolescent child is more likely to develop ureteric stones and classical renal colic [13]. More than 75% of these children will have stones composed of calcium phosphate or calcium oxalate [14], approximately 25% will have an associated urinary tract infection [15, 16] and 30% will have anatomical abnormalities that include hydronephrosis, posterior urethral valves and fused crossed renal ectopy [14]. The affected children are at risk of chronic urinary tract infections and progressive kidney disease, but treatment of the metabolic abnormality and nephrolithiasis will help to prevent these complications.

**Table 1** Genetic defects associated with some monogenic forms of hypercalciuria

| Disease                                      | Mode of inheritance | Gene | Human chromosomal location | Reference |
|----------------------------------------------|---------------------|------|-----------------------------|-----------|
| Idiopathic hypercalciuria                   | A-d                 | SAC  | 1q23.3-q24                  | [35]      |
|                                              | A-d                 | VDR  | 12q12-q14                   | [30]      |
|                                              | A-d                 | ?    | 9q33.2-q34.2                | [31]      |
| ADHH                                         | A-d                 | CASR | 3q21.1                      | [40]      |
| Hypercalciemia with hypercalciuria          | A-d                 | CASR | 3q21.1                      | [38]      |
| Bartter syndromes                           |                     |      |                             |           |
| Type I                                       | A-r                 | SLC12A1/NKCC2 | 15q15-q21.1            | [90]      |
| Type II                                      | A-r                 | KCNJ1/KCNKB | 1q24                        | [91]      |
| Type III                                     | A-r                 | CLCNKB | 1q36                      | [92]      |
| Type IV                                      | A-r                 | BSND | 1q31                        | [93]      |
| Type V                                       | A-d                 | CASR | 3q21.1                      | [48]      |
| Type VI                                      | X-r                 | CLCN5 | Xp11.22                    | [50]      |
| Dent’s disease                               | X-r                 | CLCN5 | Xp11.22                    | [52]      |
| Lowe’s syndrome                              | X-r                 | NPT2a | Xq25                      | [60]      |
| HHRH                                         | A-r                 | NPT2a/CSC34A3 | 9q34                    | [69]      |
| Nephrolithiasis, osteoporosis and hypophosphatemia | A-d                 | NPT2a/CSC34A1 | 5q35                   | [64]      |
| Familial hypomagnesemia with hypercalciuria and nephrocalcinosis | A-r | PCLN1/CLDN16 | 3q28           | [73]      |
| Familial hypomagnesemia with hypercalciuria and nephrocalcinosis with ocular abnormalities | A-r | CLDN19 | 1p34.2            | [77]      |
| dRTA with sensorineural deafness             | A-r                 | ATP6B1/ATP6V1B1 | 2p13            | [85]      |
| dRTA with preserved hearing                  | A-r                 | ATP6N1B/ATP6V0A4 | 7q34          | [88]      |

a ADHH autosomal dominant hypocalcemia with hypercalciuria, HHRH hereditary hypophosphatemic rickets with hypercalciuria, dRTA distal renal tubular acidosis

b A-d autosomal dominant, A-r autosomal recessive, X-r X-linked recessive
c SAC human soluble adenylyl cyclase; VDR vitamin D receptor; CASR calcium-sensing receptor; SLC12A1 solute carrier family 12, member 1; NKCC2 sodium–potassium–chloride co-transporter 2; KCNJ1 potassium channel, inwardly rectifying, subfamily J, member 1; ROMK renal outer medullary potassium channel; CLCNKB chloride channel Kb; BSND Barttin; CLCN5 chloride channel 5; OCRL1 oculo-cerebro-renal syndrome of Lowe 1; NPT2c/a sodium–phosphate co-transporter type 2c/a; SLC34A1/3 solute carrier family 34, member 1/3; PCLN1 paracellin; CLDN16/19 Claudin 16/19; SLC4A1 solute carrier family 4, member 1; kAE1 kidney anion exchanger 1; ATP6B1 ATPase, H+ transporting (vacuolar proton pump), V1 subunit B1; ATP6N1B ATPase, H+ transporting, lysosomal V0 subunit a4
d Bartter type III is associated with hypercalciuria but not nephrocalcinosis; Bartter type IV is not associated with persistent hypercalciuria or nephrocalcinosis, but these are included here for completeness
e Bartter type VI has been reported in one patient only, who had hypercalciuria

**Genetic epidemiology of nephrolithiasis and hypercalciuria**

The greatest risk factor for nephrolithiasis, after controlling for known dietary determinants, is having an affected family member [17], and it has been known since the 1890s that patients with renal stones are more likely than those that are not renal stone formers to have other family members affected with nephrolithiasis [18]. Thus, between 35% and 65% of renal stone formers will have relatives with nephrolithiasis, whereas only 5–20% of those that are not renal stone formers will have relatives with nephrolithiasis [17, 19, 20]. The first degree relative risk (λR) amongst recurrent stone formers has been estimated to be
between 2 and 16 [17, 21, 22]. The wide range of these estimates is largely due to differences in the study designs and the methods used to ascertain the occurrence of renal stones in relatives. Moreover, studies of twins have shown that the contributions of heritability to kidney stones and urinary calcium excretion are as high as 56% and 52%, respectively [23, 24].

Hypercalciuria, which is defined as a urinary calcium excretion in excess of 0.1 mmol/kg per 24 h or 4 mg/kg per 24 h [25, 26] is the most common metabolic abnormality associated with nephrolithiasis and is found in approximately 60% of patients with renal stones [2, 27]. Hypercalciuria may occur either as an isolated trait or in association with other metabolic abnormalities, and also as part of a renal tubular disorder. Up to 65% of patients with hypercalciuric nephrolithiasis may have a family history of the disorder [17, 19] and the inheritance may occur as that of a polygenic quantitative trait, or of a monogenic trait with either autosomal dominant, autosomal recessive or X-linked recessive modes of transmission (Table 1). The monogenic forms of hypercalciuric nephrolithiasis and their associated underlying molecular genetic mechanisms that may be associated with defects of intestinal calcium absorption, bone calcium resorption, and renal calcium reabsorption will be reviewed (Table 1).

Monogenic forms of hypercalciuria with nephrolithiasis

Idiopathic hypercalciuria

Families with idiopathic hypercalciuria (IH) and recurrent calcium oxalate stones usually reveal an autosomal dominant mode of inheritance [28]. Studies of such families have established linkage between hypercalciuric nephrolithiasis and loci on: chromosome 1q23.3-q24, which contains the human soluble adenylyl cyclase (SAC) gene [29]; chromosome 12q12-q14, which contains the vitamin D receptor (VDR) gene [30]; and chromosome 9q33.2-q34.2, from which an appropriate candidate gene remains to be identified [31].

Absorptive hypercalciuria locus on 1q23.3-24

Absorptive hypercalciuria (AH), which is characterized by increased intestinal calcium uptake, normocalcemia, normal concentrations of circulating parathyroid hormone (PTH), and low bone mineral density [32], may occur as an autosomal dominant trait [33]. Linkage studies in three families with AH, mapped the locus to chromosome 1q23.3-q24 [29] and to a region that contained a gene encoding a human SAC, which is a divalent cation and bicarbonate sensor [34]. The SAC protein, which does not respond to the heterotrimeric G protein regulators, exists freely in cytosolic and membrane-associated forms, and its cyclase catalytic activity helps to facilitate the generation of cyclic adenosine monophosphate (cAMP) in the vicinity of its targets. Mutational analysis of SAC in patients with AH revealed six sequence variations, and four of these were shown to be associated with a significantly increased relative risk for AH [35]. The manner in which these four sequence variations of SAC result in hypercalciuria and nephrolithiasis remains to be elucidated.

Vitamin D receptor and IH

Increased levels of VDR are found in circulating monocytes from patients with IH [36], and studies in a cohort of large French-Canadian families have revealed an association between IH nephrolithiasis and polymorphic loci from chromosome 12q12-q14, a region that contains the VDR gene [30]. However, DNA sequence analysis of the VDR gene did not identify any VDR mutations, but it did reveal conservative substitutions within the coding region. The role of these VDR polymorphisms in the etiology of IH nephrolithiasis remains to be explained.

Chromosome 9q33.2-q34.2 locus for autosomal dominant nephrolithiasis

A form of autosomal dominant nephrolithiasis (NPL1) has been reported in a Spanish kindred that originated from La Gomera, in the Canary Islands, and resides in Tenerife [31]. The renal stones were reported to consist of calcium oxalate, and serum and urine analyses did not reveal any significant abnormalities, although some affected members had mild hypercalciuria and some had hypomagnesemia. Linkage analysis mapped the NPL1 locus to chromosome 9q33.2-q34.2. This region contains approximately 170 genes, and, to date, the gene causing NPL1 has not been identified [31].

Calcium-sensing receptor and hypercalciuric disorders

The human calcium-sensing receptor (CaSR) is a 1,078 amino acid cell surface protein, which is predominantly expressed in the parathyroids and kidney and is a member of the family of G protein-coupled receptors. The CaSR allows regulation of PTH secretion and renal tubular calcium reabsorption in response to alterations in extracellular calcium concentrations. The human CASR gene is located on chromosome 3q21.1, and loss-of-function CaSR mutations have been reported in the hypercalcemic disorders of familial benign (hypocalciuric) hyperparathyroidism (FBHH), neonatal severe primary hyperparathyroidism (NSHPT) and familial isolated hyperparathyroidism
(FIHP). However, gain-of-function CaSR mutations result in autosomal dominant hypocalcemia with hypercalciuria (ADHH) and Bartter’s syndrome type V.

Familial isolated primary hyperparathyroidism due to CaSR mutations

Hereditary disorders associated with hypercalcemia include familial isolated primary hyperparathyroidism (FIHP), familial benign hypocalciuric hypercalcaemia (FBHH), multiple endocrine neoplasia type 1 (MEN1), MEN type 2 (MEN2), and the hyperparathyroidism–jaw tumor (HPT-JT) syndrome. The hypercalcaemia of FIHP, MEN1, MEN2, and HPT-JT (Table 2) is associated with hypercalciuria and sometimes kidney stones, whereas that of FBHH is associated with a low urinary calcium–creatinine clearance ratio (<0.01). In FBHH, which is an autosomal dominant disorder, the hypercalcaemia is usually mild to moderate, i.e. within 10% of the upper limit of normal, although some patients do have more severe hypercalcaemia [37]. Other biochemical features include mild hypermagnesemia and normal or mildly elevated serum PTH concentrations. FBHH is due to inactivating mutations of the CASR gene, which is located on chromosome 3q21.1, whereas the genes causing MEN1, MEN2 and HPT-JT are located on chromosomes 11q13, 10q11.2, and 1q31.2, respectively. Some patients with FIHP have mutations of the MEN1, HPT-JT and CaSR genes, although the majority of FIHP patients do not have such mutations and the genes involved need to be characterized. Five CaSR mutations (Thr100Ile, Lys336-deletion, Leu650Pro, Val689Met and Phe881Leu) have been reported in FIHP [38, 39]. Functional characterization of the mutant Phe881Leu CaSR only, has been undertaken in HEK293 cells, and this demonstrated that the Phe881Leu mutation resulted in a loss of function [38]. Thus, although the majority of loss-of-function CaSR mutations will lead to FBHH, some may result in hypercalcemic adenoma formation.

Autosomal dominant hypocalcemic hypercalciuria

Patients with ADHH usually have mild hypocalcemia that is generally asymptomatic, but it may, in some patients, be associated with carpo-pedal spasm and seizures [40]. The serum phosphate concentrations in patients with ADHH are either elevated or in the upper–normal range, and the serum magnesium concentrations are either low or in the low–normal range [40]. These biochemical features of hypocalcemia, hyperphosphatemia and hypomagnesemia are consistent with hypoparathyroidism and pseudo-hypoparathyroidism. However, these patients have serum PTH concentrations that are in the low–normal range [40–44]. Thus, they are not hypoparathyroid, which would be associated with undetectable serum PTH concentrations, or pseudo-hypoparathyroid, which would be associated with elevated serum PTH concentrations. These patients were therefore classified as having autosomal dominant hypocalcemia (ADH) [41], and the association of hypercalciuria with this condition led to its being referred to as autosomal dominant hypocalcemia with hypercalciuria (ADHH) [40]. Treatment with active metabolites of vitamin D to correct the hypocalcemia has been reported to result in marked hypercalciuria, nephrocalcinosis, nephrolithiasis and renal impairment, which was partially reversible after cessation of the vitamin D treatment [40]. Thus, it is important to identify and restrict the use of vitamin D treatment in such ADHH patients and their families whose hypocalcemia is due to a gain-of-function CaSR mutation and not hypoparathyroidism [40]. More than 40 different CASR mutations have been identified in ADHH patients, and over 50% of these are in the extracellular domain [40–45]. Almost every ADHH family has its own unique missense heterozygous CASR mutation [45]. Studies of the expression of ADHH-associated CaSR mutations have demonstrated a gain-of-function, whereby there is a leftward shift in the dose–response curve, such that the extracellular calcium concentration needed to produce a half-maximal effective concentration (EC50)

| Disorder | Clinical features | Gene product | Chromosomal location of the gene |
|----------|------------------|--------------|----------------------------------|
| FIHP | Familial isolated parathyroid tumors | Menin | 11q13 |
| FBHH | Parathyroid hyperplasia and/or tumors associated with pituitary and pancreatico-duodenal neuro-endocrine tumors | Parafibromin | 1q31.2 |
| MEN1 | Parathyroid hyperplasia and/or tumors associated with pituitary and pancreatico-duodenal neuro-endocrine tumors | CaSR | 3q21.1 |
| MEN2a | Parathyroid tumors with medullary thyroid cancer and pheochromocytoma | Menin | 11q13 |
| HPT-JT | Parathyroid tumors with ossifying fibromas of the jaw | Ret | 10q11.2 |
| | | Parafibromin | 1q31.2 |
increase in total intracellular calcium ions (or inositol trisphosphate, \( \text{IP}_3 \)) is significantly lower than that required for the wild-type receptor [40, 41].

**Bartter syndrome type V**

Bartter syndrome is a heterogeneous group of autosomal hereditary disorders of electrolyte homeostasis characterized by hypokalemic alkalosis, renal salt wasting that may lead to hypotension, hyperreninemic hyperaldosteronism, increased urinary prostaglandin excretion, and hypercalciuria with nephrocalcinosis [46, 47]. Mutations of several ion transporters and channels have been associated with Bartter syndrome, and six types (Table 1) are now recognized [47]. Thus, type I is due to mutations involving the bumetanide-sensitive sodium–potassium–chloride co-transporter (NKCC2 or SLC12A1); type II is due to mutations of the renal outer-medullary potassium (ROMK) channel; type III is due to mutations of the voltage-gated chloride channel, CLC-Kb; type IV is due to mutations of barttin, which is a beta sub-unit that is required for trafficking of CLC-Kb and CLC-Ka, and this form is also associated with deafness as barttin, CLC-Ka and CLC-Kb are also expressed in the marginal cells of the scala media of the inner ear that secrete potassium ion-rich endolymph; and type V is due to activating mutations of the CaSR. Patients with Bartter syndrome type V have the classical features of the syndrome, i.e. hypokalemic metabolic alkalosis, hyper-reninemia and hyperaldosteronism [48, 49]. In addition, they develop hypocalcemia, which may be symptomatic and lead to carpo-pedal spasm, and an elevated fractional excretion of calcium, that may be associated with nephrocalcinosis [48, 49]. Such patients have been reported to have heterozygous gain-of-function CaSR mutations, and in vitro functional expression of these mutations not only revealed a leftward shift in the dose–response curve for the receptor, but also showed them to have a much lower EC\(_{50}\) than that found in patients with ADHH [47–49]. This suggests that the additional features that occur in Bartter syndrome type V when compared to ADHH are due to severe gain-of-function mutations of the CaSR [47]. Bartter syndrome type VI has been reported in one child from Turkey [50] and was associated with a CLCN5 mutation; the latter are usually seen in Dent’s disease (see below).

**Dent’s disease**

Dent’s disease is an X-linked recessive renal tubular disorder characterized by low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, nephrolithiasis, and eventual renal failure [51]. Dent’s disease is also associated with the other multiple proximal tubular defects of the renal Fanconi syndrome, which include aminoaciduria, phosphaturia, glycosuria, kaliuresis, uricosuria, and impaired urinary acidification [51]. With the exception of rickets, which occurs in a minority of patients, there appear to be no extra-renal manifestations in Dent’s disease [51]. The gene causing Dent’s disease, CLCN5, encodes the chloride/proton antiporter CLC-5 [52]. CLC family members, which are usually voltage-gated chloride channels, have important diverse functions that include the control of membrane excitability, transepithelial transport and regulation of cell volume [53]. CLC-5, which is predominantly expressed in the kidney and, in particular, the proximal tubule, thick ascending limb of Henle, and the alpha intercalated cells of the collecting duct, has been reported to be critical for acidification in the endosomes that participate in solute re-absorption and membrane recycling in the proximal tubule [54, 55]. CLC-5 is also known to alter membrane trafficking via the receptor-mediated endocytic pathway that involves megalin and cubulin [56]. CLC-5 mutations associated with Dent’s disease impair chloride flow and likely lead to impaired acidification of the endosomal lumen and, thereby, also disrupt trafficking of endosomes back to the apical surface [56]. This will result in impairment of solute reabsorption by the renal tubule and in the defects observed in Dent’s disease [57]. Mice that are deficient for CLC-5 develop the phenotypic abnormalities associated with Dent’s disease [57]. Mutations of the gene encoding an inositol polyphosphate 5-phosphatase result in Lowe syndrome (see below) and also Dent’s disease [58].

**Oculo-cerebro-renal syndrome of Lowe**

The oculo-cerebro-renal syndrome of Lowe (OCRL) is an X-linked recessive disorder that is characterized by congenital cataracts, mental retardation, muscle hypotonia, rickets, and defective proximal tubular reabsorption of bicarbonate, phosphate and amino acids. Some patients may also develop hypercalciuria and renal calculi [59]. The disease is nearly always confined to boys, who develop renal dysfunction in the first year of life, have delayed bone age and reduced height, and may die in childhood. Female carriers who have normal neurological and renal function can be identified in 80% of cases by micro-punctate cortical lens opacities. The Lowe syndrome gene, *OCRL1*, is located on Xq25 and encodes a member of the type II family of inositol polyphosphate 5-phosphatases [60]. These enzymes hydrolyze the 5-phosphate of inositol 1,4,5-trisphosphate and of inositol 1,3,4,5-tetrakisphosphate, phosphatidylinositol 4,5-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate, thereby presumably inactivating them as second messengers in the phosphatidylinositol signaling pathway [61]. The preferred substrate of OCRL1 is phosphatidylinositol 4,5-bisphosphate, and this lipid accumulates in the
renal proximal tubular cells of patients with Lowe syndrome [61]. OCRL1 is localized to lysosomes in renal proximal tubular cells and to the trans-Golgi network in fibroblasts. This localization is consistent with the role of OCRL1 in lysosomal enzyme trafficking from the trans-Golgi network to lysosomes, and the activities of several lysosomal hydrolases are found to be elevated in the plasma of affected patients [62]. OCRL1 has also been shown to interact with clathrin and indeed co-localizes with clathrin on endosomal membranes that contain transferrin and mannose 6-phosphate receptors [63]. Mannose 6-phosphate receptor-bound lysosomal enzymes are recruited by appendage (AP) subunits and Golgi-localized binding proteins into clathrin-coated vesicles that transport them from the trans-Golgi network to endosomes [63]. Thus, it seems likely that the OCRL1 mutations in Lowe syndrome patients result in OCRL1 protein deficiency, which leads to disruptions in lysosomal trafficking and endosomal sorting. This abnormality is similar to that observed in Dent’s disease, and it is of interest to note that some patients with the latter disease, who had no demonstrable CLC-5 mutations, were found instead to have OCRL1 mutations [58]. The absence of cataracts in patients with Dent’s disease due to OCRL1 mutations was the major phenotypic difference found when such patients were compared with patients with Lowe syndrome [58]. The molecular and cellular basis of these phenotypic differences still remains to be elucidated.

Hereditary hypophosphatemic rickets with hypercalciuria

Two different heterozygous mutations (Ala48Phe and Val147Met) in NPT2a (also referred to as SLC34A1), the gene encoding a sodium-dependent phosphate transporter, have been reported in patients with urolithiasis or osteoporosis and persistent idiopathic hypophosphatemia due to decreased phosphate reabsorption by the renal tubules [64]. When expressed in Xenopus laevis oocytes, the mutant NPT2a showed impaired function. However, these in vitro findings were not confirmed in another study using oocytes and opossum kidney (OK) cells, raising the concern that the NPT2a mutation identified could not explain the findings in the patients described [65]. However, homozygous ablation of Npt2a in mice (Npt2a-/-) results in increased urinary phosphate excretion, hypophosphatemia, an appropriate elevation in the serum levels of 1,25-dihydroxyvitamin D, hypercalciemia, decreased serum parathyroid hormone levels, increased serum alkaline phosphatase activity and hypercalciuria (see below) [66]. Some of these biochemical features are observed in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH), but there are important differences [67]. Thus, HHRH patients develop rickets, short stature, with an increased renal phosphate clearance, hypercalciuria, but have normal serum calcium levels, increased gastrointestinal absorption of calcium and phosphate due to an elevated serum concentration of 1,25-dihydroxyvitamin D, suppressed parathyroid function and normal urinary cAMP excretion [67]. However, HHRH patients do not have NPT2a mutations [68], and studies have demonstrated that HHRH patients harbor homozygous or compound heterozygous mutations of SLC34A3, the gene encoding the sodium–phosphate co-transporter NPT2c [69, 70]. These findings indicate that NPT2c has a more important role in phosphate homeostasis than was previously thought.

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis due to paracellin-1 (claudin 16) mutations

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal recessive renal tubular disorder that is frequently associated with progressive kidney failure [71]. FHHNC often presents in childhood, with seizures, or tetany due to hypocalcemia and hypomagnesemia. Other recurrent clinical manifestations include urinary tract infections, polyuria, polydipsia, and failure to thrive. Investigations reveal hypomagnesemia, hypocalcemia, hyperuricemia, hypermagnesuria, hypercalciuria, incomplete acidification in the distal renal tubules, hypocitraturia and renal calcification [72]. Treatment consists of high doses of magnesium, administered enterally, to restore normomagnesemia. Children with FHHNC who receive such treatment early, develop normally. Studies of linkage in 12 FHHNC kindreds found the disease locus to be on chromosome 3q27, and positional cloning studies identified mutations in the gene encoding paracellin-1 (PCLN-1), which is also referred to as claudin 16 (CLDN16) [72]. FHHNC patients were either homozygotes or compound heterozygotes for PCLN-1 mutations, consistent with the autosomal recessive inheritance of the disorder [73]. The PCLN-1 mutations consisted of premature termination codons, splice-site mutations and missense mutations [72–74]. The PCLN-1 protein, which consists of 305 amino acids, has sequence and structure similar to those of the members of the claudin family and is, therefore, also referred to as CLDN16 [72]. Claudins are membrane-bound proteins that form the intercellular tight junction barrier in a variety of epithelia [75]. Claudins have four transmembrane domains and intracellular amino- and carboxy-termini. The two luminal loops mediate cell–cell adhesion via homo- and hetero-typic interactions with claudins on a neighboring cell. In addition, claudins form paracellular ion channels, which facilitate renal tubular paracellular transport of solutes [75]. CLDN16 is exclusively expressed in the thick ascending limb of Henle’s
loop, where it forms the paracellular channels that are driven by an electrochemical gradient and allow reabsorption of calcium and magnesium [76]. Hence, loss of function of CLDN16 that would arise from FHHNC mutations would result in urinary calcium and magnesium loss and lead to hypocalcemia and hypomagnesemia, respectively. A CLDN16 missense mutation (Thr233Arg) has also been identified in two families with self-limiting childhood hypercalciuria [74]. The hypercalciuria decreased with age and was not associated with progressive renal failure. The Thr233Arg mutation resulted in inactivation of a PDZ-domain binding motif, and this disrupted the association with the tight junction scaffolding protein, zona occludens (ZO)-1 [74], with accumulation of the mutant CLDN16 protein in lysosomes and no localization to the tight junctions. Thus, CLDN16 mutations may result in different abnormalities in the function of renal tubular cells and, hence, lead to differences in the clinical phenotype. A form of FHHNC with severe ocular involvement reported in one Swiss and eight Spanish/Hispanic families was recently mapped to chromosome 1p34.2 [77]. This region contains *CLDN19*, the gene that encodes claudin 19, a tight-junction protein expressed in the kidney and eye. A Gly20Asp mutation located in the first transmembrane domain of CLDN19 was identified in all but one of the Spanish/Hispanic families, and a Gln57Glu mutation in the first extracellular loop of CLDN19 was found in the Swiss family. In addition, a Leu90Pro mutation in CLDN16 was identified in a consanguineous family of Turkish origin with FHHNC and severe ocular involvement [77].

Distal renal tubular acidosis

In distal renal tubular acidosis (dRTA) the tubular secretion of hydrogen ions in the distal nephron is impaired, and this results in a metabolic acidosis that is often associated with hypokalemia due to renal potassium wasting, hypercalciuria with nephrocalcinosis, and metabolic bone disease. Distal RTA may be familial, with autosomal dominant or recessive inheritance. One form of autosomal dominant dRTA is due to mutations of the erythrocyte anion exchanger (band 3, AE1). Two autosomal recessive forms of dRTA are caused by mutations of sub-units of the H⁺-ATPase (proton) pump. Thus, dRTA associated with sensorineural deafness is associated with mutations of the gene encoding the B1 subunit of the apical H⁺-ATPase pump (referred to as ATP6B1 or ATP6V1B1), whilst dRTA without deafness is caused by

---

**Fig. 1 Suggested algorithm for the investigation of a child with hypercalciuria and nephrolithiasis/nephrocalcinosis, based initially on measurements of plasma calcium and PTH.**

For the hypocalcemic patient, hypoparathyroidism in this context, i.e. in association with hypercalciuria, is rare and is included here for completeness. One study of 85 patients with hypoparathyroidism and 15 ADHH patients has shown that prior to their treatment with vitamin D to correct the hypocalcemia, the urinary calcium/creatinine ratio in ADHH patients was generally higher than that found in patients with hypoparathyroidism, although there was an overlap [94]. Following treatment with vitamin D, the urinary calcium/creatinine ratios in ADHH and hypoparathyroid patients were similar [94]. Hence, it may be difficult for patients with hypoparathyroidism to be distinguished from those with ADHH on the sole basis of urinary calcium excretion evaluations [94].
mutations of the gene encoding a different subunit, ATP6N1B (also referred to as ATP6V0A4), which is an isoform of ATP6N1A that is the 116 kDa non-catalytic accessory subunit of the proton pump.

**Autosomal dominant dRTA due to erythrocyte anion exchanger (Band 3) mutations**

The family of anion exchangers (AEs) is widely distributed and involved in the regulation of trans-cellular transport of acid and base across epithelial cells, cell volume and intracellular pH [78]. For example, AE1, which is a major glycoprotein of the erythrocyte membrane, mediates exchange of chloride and bicarbonate [79]. AE1 is also found in the basolateral membrane of the α-intercalated cells of renal collecting ducts, which are involved in acid secretion [80]. Patients with autosomal dominant dRTA, the majority of whom had hypercalciuria, renal stones and nephrocalcinosis and a few of them who had erythrocytosis, were found to have AE1 mutations [81]. These AE1 mutations resulted in several functional abnormalities that included reductions in chloride transport, and trafficking defects that led to cellular retention of AE1 or mis-targeting of AE1 to the apical membrane [82, 83]. AE1 mutations may also be associated with autosomal recessive dRTA in Southeast Asian kindreds that have ovalocytosis [84].

**Autosomal recessive distal renal tubular acidosis due to proton pump mutations**

Proton pumps (H⁺-ATPase) are ubiquitously expressed, and one such multi-unit H⁺-ATPase is found in abundance on the apical (luminal) surface of the α-intercalated cells of the cortical collecting duct, which regulates urinary acidification. Failure of vectorial proton transport by these α-intercalated cells results in the duct’s inability to acidify the urine and in disorders of dRTA. The molecular basis of two types of autosomal recessive dRTA due to proton pump abnormalities has been characterized. The gene causing one type of autosomal recessive dRTA that was associated with sensorineural hearing loss was mapped to chromosome 2p13, which contained the ATP6B1 gene that encodes the B1 subunit of the apical proton pump (H⁺-ATPase) [85]. Mutations that would likely result in a functional loss of ATP6B1 were identified in over 30% of families with this form of autosomal recessive dRTA that occurred with deafness in >85% of families [85]. The association of dRTA and deafness is consistent with the renal and cochlear expression of ATP6B1 [86, 87]. ATP6B1 plays a critical role in regulating the pH of the inner ear’s endolymph, and dysfunction of this would lead to an alkaline micro-environment in the inner ear, which has been proposed to impair hair cell function and result in progressive deafness [85, 87]. The gene causing autosomal recessive dRTA with normal hearing was localized to chromosome 7q33-q34, which contained the ATP6N1B gene that encodes the non-catalytic accessory subunit of the proton pump of the α-intercalated cells of the collecting duct [88]. ATP6N1B mutations, which are predicted to result in a functional loss, were identified in >85% of kindreds with autosomal recessive dRTA associated with normal hearing, and this is consistent with the expression of ATP6N1B in the kidney and not other organs. Approximately 15% of families with autosomal recessive dRTA were not found to have mutations in ATP6B1 or ATP6N1B mutations, and this indicates that mutations in other genes are likely to be involved in the etiology of autosomal recessive dRTA [89].

**Conclusions**

Although kidney stones are an infrequent occurrence in children, they are, nevertheless, important causes of abdominal pain, urinary tract infection and progressive renal failure. Renal stones in children are associated with a metabolic abnormality in approximately 50% of patients, and treatment of this will help to prevent long-term complications. Thus, the investigation of hypercalciuric nephrolithiasis requires an assessment for these metabolic abnormalities, and a measurement of plasma and urinary electrolytes and metabolites is of importance. An approach to the diagnosis of these complex disorders, based upon the assessment of plasma calcium and PTH in a child with hypercalciuria, is outlined in Fig. 1. These metabolic disorders are often inherited and associated with hypercalciuria (Table 1), and studies of these disorders have elucidated some of the renal tubular transport mechanisms that regulate calcium reabsorption.

**Acknowledgments**

Funding grants were received from: Kidney Research UK (M.J.S. and R.V.T.), The European Union, EuReGene FP6 (N.Y. L., R.V.T.), The Medical Research Council (R.V.T.), The Wellcome Trust (N.Y.L., R.V.T.) and the University of Oxford (N.Y.L.).

**Conflict of interest statement**

The authors declare that they have no conflicts of interest

**Questions**

(Answers appear after the reference list)

1. Which of the following does NOT constitute a major risk factor for the development of kidney stones in children?
a. Anatomical abnormalities
b. Family history
c. Hypercalciuria
d. Urinary tract infection
e. Hypocalcemia

2. Which form of Bartter’s syndrome is NOT associated with nephrocalcinosis?
   a. Type I
   b. Type II
   c. Type III
   d. Type V
   e. Type VI

3. The Bartter syndromes are characterized by which of the following clinical and biochemical features?
   a. Hyperkalemia
   b. Hypercalciemia
   c. Metabolic alkalosis
   d. It is always associated with an autosomal recessive mode of transmission
   e. It may be associated with a defect in anion exchanger 1

4. Which of the following statements concerning idiopathic hypercalciuria (IH) is TRUE?
   a. It is associated with 24-hour urinary calcium excretion of <0.1 mmol/kg
   b. It may be associated with increased intestinal absorption of calcium
   c. Families with IH often have recurrent calcium oxalate stones which have an autosomal recessive mode of inheritance
   d. Mutations in the vitamin D receptor is a common cause of idiopathic hypercalciuria

5. Which of the following is NOT due to a mutation in the CaSR gene?
   a. FIHP
   b. Bartter’s syndrome
   c. ADHH
   d. Dent’s disease
   e. FBHH

References

1. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817–1823
2. Frick KK, Bushinsky DA (2003) Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol 14:1082–1095
3. Scheinman SJ (1999) Nephrolithiasis. Semin Nephrol 19:381–388
4. Kroovand RL (1997) Pediatric urolithiasis. Urol Clin North Am 24:173–184
5. Cohen TD, Ehret J, King LR, Preminger GM (1996) Pediatric urolithiasis: medical and surgical management. Urology 47:292–303
6. Robertson WG, Peacock M, Marshall RW, Speed R, Nordin BE (1975) Seasonal variations in the composition of urine in relation to calcium stone-formation. Clin Sci Mol Med 49:597–602
7. Moe OW, Bonny O (2005) Genetic hypercalciuria. J Am Soc Nephrol 16:729–745
8. Parry ES, Lister IS (1975) Sunlight and hypercalciuria. Lancet 1:1063–1065
9. Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328:833–838
10. Serio A, Fraioli A (1999) Epidemiology of nephrolithiasis. Nephron 81 [Suppl 1]:26–30
11. Stapleton FB (2002) Childhood stones. Endocrinol Metab Clin North Am 31:1001–1015
12. Schwarz RD, Dwyer NT (2006) Pediatric kidney stones: long-term outcomes. Urology 67:812–816
13. Cameron MA, Sakhaee K, Moe OW (2005) Nephrolithiasis in children. Pediatr Nephrol 20:1587–1592
14. Milliner DS, Murphy ME (1993) Urolithiasis in pediatric patients. Mayo Clin Proc 68:241–248
15. Gearhart JP, Herzberg GZ, Jeffs RD (1991) Childhood urolithiasis: experiences and advances. Pediatrics 87:445–450
16. Choi H, Snyder HM, Duckett JW (1987) Urolithiasis in childhood: current management. J Pediatr Surg 22:158–164
17. Resnick M, Prudden DB, Goodman HO (1968) Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med 278:1313–1318
18. Clubbe WH (1894) Family disposition to urinary concretions. Lancet 1:823
19. Polito C, La Manna A, Nappi B, Villani J, Di Toro R (2000) Idiopathic hypercalciuria and hyperuricosuria: family prevalence of nephrolithiasis. Pediatr Nephrol 14:1102–1104
20. Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1997) Family history and risk of kidney stones. J Am Soc Nephrol 8:1568–1573
21. McGeown MG (1960) Heredity in renal stone disease. Clin Sci 19:465–471
22. Trinchieri A, Mandressi A, Luongo P, Coppi F, Pisani E (1988) Familial aggregation of renal calcium stone disease. J Urol 139:478–481
23. Goldfarb DS, Fischer ME, Keich Y, Goldberg J (2005) A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 67:1053–1061
24. Hunter DJ, Lange M, Snieder H, MacGregor AJ, Swaminathan R, Thakker RV, Spector TD (2002) Genetic contribution to renal function and electrolyte balance: a twin study. Clin Sci (Lond) 103:259–265
25. Audran M, Legrand E (2000) Hypercalciuria. Joint Bone Spine 67:509–515
26. Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59:2290–2298
27. Pak CY (1997) Nephrolithiasis. Curr Ther Endocrinol Metab 6:572–576
28. Cee FL, Parks JH, Moore ES (1979) Familial idiopathic hypercalciuria. N Engl J Med 300:337–340
29. Reed BY, Heller HJ, Gitomer WL, Pak CY (1999) Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J Clin Endocrinol Metab 84:3907–3913
30. Scott P, Ouimet D, Valiquette L, Guay G, Proulx Y,Trouve ML, Gagnon B, Bonnardeaux A (1999) Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 10:1007–1013
31. Wolf MT, Zalewski I, Martin FC, Ruf R, Muller D, Hennies HC, Schwarz S, Panther F, Attanasio M, Acosta HG, Imm A, Lucke B, Utsch B, Otto E, Nurnberg P, Nieto VG, Hildebrandt F (2005) Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis to chromosome 9q33.2-q34.2 by total genome search for linkage. Nephrol Dial Transplant 20:909–914

32. Pak CY, Kaplan R, Bone H, Townsend J, Waters O (1975) A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med 292:497–500

33. Pak CY, McGuire J, Peterson R, Britton F, Harrod MJ (1981) Familial absorptive hypercalciuria in a large kindred. J Urol 126:717–719

34. Geng W, Wang Z, Zhang J, Reed BY, Pak CY, Moe OW (2005) Cloning and characterization of the human soluble adenylylcyclase. Am J Physiol Cell Physiol 288:C1305–1316

35. Reed BY, Gitomer WL, Heller HJ, Suh MC, Lemke M, Padalino P, Pak CY (2002) Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 87:1476–1485

36. Favus MJ, Karnauskas AJ, Parks JH, Coe FL (2004) Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 89:4937–4943

37. Heath H 3rd (1989) Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. Endocrinol Metab Clin North Am 18:723–740

38. Carling T, Szabo E, Bae M, Riddlefelt P, Westin G, Gustavsson P, Trivedi S, Hellman P, Brown EM, Dahl N, Rastad J (2000) Familial hypercalciuria and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85:2042–2047

39. Warner J, Epstein M, Sweet A, Singh D, Burgess J, Stranks S, Hill P, Perry-Keene D, Learoyd D, Robinson B, Birdsey P, Mackenzie E, Teh BT, Prins JB, Cardinal J (2004) Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 41:155–160

40. Pearce SH, Williamson C, Kiófor O, Bae M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV (1996) A familial syndrome of hypocalciuria with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335:1115–1122

41. Dickson MR, Brown EM, Eisen H, Cale PN, Kiófor O, Park J, Hebert SC, Seidman CE, Seidman JG (1994) Autosomal dominant hypocalciuria caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 8:303–307

42. Finegold DN, Armitage MM, Galiani M, Matise TC, Pandian MR, Perry YM, Deka R, Ferrrell RE (1994) Preliminary localization of a gene for autosomal dominant hyperparathyroidism to chromosome 3q13. Pediatr Res 36:414–417

43. Perry Y, Finegold D, Armitage M, Ferrrell R (1994) A missense mutation in the Ca-sensing receptor causes familial autosomal dominant hyperparathyroidism. Am J Hum Genet 55:A17

44. Baron J, Winer KC, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB (1996) Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hyperparathyroidism. Hum Mol Genet 5:601–606

45. Hendy GN, D’Souza-Li L, Yang B, Canaff L, Cole DE (2000) Mutations of the calcium-sensing receptor (CASR) in familial hypercalciuric hypercalciuria, neonatal severe hyperparathyroïdism, and autosomal dominant hypocalciuria. Hum Mutat 16:281–296

46. Thakker RV (2000) Molecular pathology of renal chloride channels in Dent’s disease and Bartter’s syndrome. Exp Nephrol 8:351–360

47. Hebert SC (2003) Bartter syndrome. Curr Opin Nephrol Hypertens 12:527–532

48. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T (2002) Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. Lancet 360:692–694

49. Vargas-Poussou R, Huang C, Hulin P, Houllier P, Jeunemaitre X, Paillard M, Planell GS, Dechaux M, Miller RT, Antignac C (2002) Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalciuria with a Bartter-like syndrome. J Am Soc Nephrol 13:2259–2266

50. Besbas N, Ozalpin F, Jekk N, Seyberth H, Ludwig M (2005) CLCN5 mutation (R347X) associated with hypokalaemic metabolic alkalosis in a Turkish child: an unusual presentation of Dent’s disease. Nephrol Dial Transplant 20:1476–1479

51. Wong OM, Norden AG, Feest TG (1994) Dent’s disease: a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. J QIM 87:473–493

52. Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwappach B, Scheinman SJ, Harding B, Bolino A, Devoto M, Goodyer P, Rigden SP, Wong O, Jentsch TJ, Craig IW, Thakker RV (1996) A common molecular basis for three inherited kidney stone diseases. Nature 379:445–449

53. Jentsch TJ, Neagoe I, Scheel O (2005) CLC chloride channels and transporters. Curr Opin Neurobiol 15:319–325

54. Gunther W, Luchow A, Cluzeaud F, Vandewalle A, Jentsch TJ (1998) CIC-5, the chloride channel mutated in Dent’s disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci U S A 95:8075–8080

55. Devuyyst O, Christie PT, Courtoy PJ, Beuwens R, Thakker RV (1999) Intra-renal and subcellular distribution of the human chloride channel, CIC-5, reveals a pathophysiological basis for Dent’s disease. Hum Mol Genet 8:247–257

56. Piton N, Gunther W, Schwake M, Bosl MR, Jentsch TJ (2000) CIC-5 Cl−channel disruption impairs endocytosis in a mouse model for Dent’s disease. Nature 408:369–373

57. Gunther W, Piton N, Jentsch TJ (2003) The CIC-5 chloride channel knock-out mouse—an animal model for Dent’s disease. Pflugers Arch 445:456–462

58. Hoopes RR, Shrimpton AE, Knoll SJ, Huerer P, Hoppe B, Matyus J, Simokes A, Tasic V, Toeschoff B, Suchy SF, Nussbaum RL, Scheinman SJ (2005) Dent disease with mutations in OCRL1. Am J Hum Genet 76:260–267

59. Sloman GA, Winters WD, Shaw DW, Avner ED (1995) Hypercalciuria and nephrocalcinosis in the oculocerebrorenal syndrome. J Urol 153:1244–1246

60. Leehey AM, Charnas LR, Nussbaum RL (1993) Nonsence mutations in the OCRL-1 gene in patients with the oculocerebrorenal syndrome of Lowe. Hum Mol Genet 2:461–463

61. Zhang X, Hartz PA, Philip E, Racusen LC, Majerus PW (1998) Cell lines from kidney proximal tubules of a patient with Lowe syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4,5-bisphosphate. J Biol Chem 273:1574–1582

62. Ungewickell AJ, Majerus PW (1999) Increased levels of plasma lysosomal enzymes in patients with Lowe syndrome. Proc Natl Acad Sci U S A 96:13342–13344

63. Lowe M (2005) Structure and function of the Lowe syndrome protein OCRL1. Traffic 6:711–719

64. Prie D, Huart V, Bakouh N, Planelles G, Dells O, Gerard B, Hulin P, Benque-Blanchet F, Silve C, Grandchamp B, Friedlander G (2002) Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347:983–991

65. Virkki LV, Forster IC, Hernando N, Biber J, Murer H (2003) Functional characterization of two naturally occurring mutations in the human sodium-phosphate cotransporter type IIa. J Bone Miner Res 18:2135–2141
66. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS (1998) Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A 95:5372–5377

67. Tiede M, Daud D, Samuel R, Arie R, Halabe A, Bab I, Gabizon D, Liberman UA (1985) Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 312:611–617

68. Jones A, Tzenova J, Frappier D, Crumley M, Roslin N, Kos C, Tiede M, Langman C, Proesmans W, Carpenter T, Rice A, Anderson D, Morgan K, Fujiwara T, Tenenhouse H (2001) Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the NaPi cotransporter NPT2 gene. J Am Soc Nephrol 12:507–514

69. Bergwitz C, Roslin NM, Tiede M, Loredano-Osti J, Basteppe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson D, Garabedian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Jumper H (2006) SLC34A3 Mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-2lc in maintaining phosphate homeostasis. Am J Hum Genet 78:179–192

70. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabl D, Hochberg Z, Strom TM (2006) Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78:193–201

71. Paunier L, Radde IC, Kooh SW, Conen PE, Fraser D (1968) Primary hypomagnesaemia with secondary hypercalcaemia in an infant. Pediatrics 41:385–402

72. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP (1999) Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285:103–106

73. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Peters M, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Tenenhouse HS, Jumper H (2001) Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 12:1872–1881

74. Muller D, Kaasalya PJ, Claverie-Martín F, Meij IC, Eggert P, Garcia-Nieto V, Hunziker W (2003) A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am J Hum Genet 73:1293–1301

75. Colegio OR, Van Itallie CM, McCrea HJ, Rahner C, Anderson JM (2002) Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am J Physiol Cell Physiol 283:C142–C147

76. Konrad M, Schlingmann KP, Gudermann T (2004) Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 286:F599–F605

77. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzhum H, Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Arcieto G, Cano F, Enriquez R, Juppner H, Bakkaloglu A, Hediger MA, Gallati S, Neuhaus SS, Nurnberg P, Weber S (2006) Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79:949–957

78. Kopito RR (1990) Molecular biology of the anion exchanger gene family. Int Rev Cytol 123:177–199

79. Tanner MJ (1993) Molecular and cellular biology of the erythrocyte anion exchanger (AE1). Semin Hematol 30:34–57

80. Wagner S, Vogel R, Lietzke R, Koob R, Drenckhahn D (1987) Immunohistochemical characterization of a band 3-like anion exchanger in collecting duct of human kidney. Am J Physiol 253:F213–221

81. Bruce LJ, Cope DL, Jones GK, Schofield AE, Burley M, Povey S, Unwin RJ, Wrong O, Tanner MJ (1997) Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 100:1693–1707

82. Bruce LJ, Wrong O, Toye AM, Young MT, Ogle G, Ismail Z, Sinha AK, McMPeter M, Hwailewanje I, Nash GB, Hart S, Lavu E, Palmer R, Othman A, Unwin RJ, Tanner MJ (2000) Band 3 mutations, renal tubular acidosis and South-East Asian ovalocytosis in Malaysia and Papua New Guinea: loss of up to 95% band 3 transport in red cells. Biochem J 350(Pt 1):41–51

83. Toye AM (2005) Defective kidney anion-exchanger 1 (AE1, Band 3) trafficking in dominant distal renal tubular acidosis (dRTA). Biochem Soc Symp 72:47–63

84. Wrong O, Bruce LJ, Unwin RJ, Toye AM, Tanner MJ (2002) Band 3 mutations, distal renal tubular acidosis, and Southeast Asian ovalocytosis. Kidney Int 62:10–19

85. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano J, Santos F, Cremers CW, Di Pietro A, Hofbrand BI, Winiarski J, Bakkaloglu A, Ozen S, Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, Cunningham MJ, Jha V, Lifton RP (1999) Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 21:84–90

86. Nelson RD, Guo XL, Masood K, Brown D, Kalkbrenner M, Gluck S (1992) Selectively amplified expression of an isofrom of the vacuolar H(+)-ATPase 56-kilodalton subunit in renal intercalated cells. Proc Natl Acad Sci U S A 89:3541–3545

87. Stankovic KM, Brown D, Alper SL, Adams JC (1997) Localization of pH regulating proteins H+ATPase and Cl-/HCO3-exchanger in the guinea pig inner ear. Hear Res 114:21–34

88. Smith AN, Skaug J, Choate KA, Nayir A, Bakkaloglu A, Ozen S, Hulton SA, Sanjad SA, Al-Sabban EA, Lifton RP, Scherer SW, Karet FE (2000) Mutations in ATP6V1B1, encoding a new kidney vacuolar proton pump 116-kD subunit, cause renal tubular acidosis with preserved hearing. Nat Genet 26:71–75

89. Stover EH, Borthwick KJ, Bavalia C, Eady N, Fritz DM, Rungroj N, Giersch AB, Morton CC, Axon PR, Akil I, Al-Sabban EA, Baguley DM, Bianca S, Bakkaloglu A, Bircan L, Chauveau D, Clermont MJ, Guala A, Hulton SA, Kroebs H, Li Volti G, Mir S, Mocan H, Nayir A, Ozen S, Rodriguez Soriano J, Sanjad SA, Tasic V, Taylor CM, Topaloglu R, Smith AN, Karet FE (2002) Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet 39:796–803

90. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 13:183–188

91. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Rodriguez-Soriano J, Sanjad SA, Tasic V, Taylor CM, Topaloglu R, Smith AN, Karet FE (2002) Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet 39:796–803

92. Zelikovic I, Szargel R, Hawash A, Labay V, Hatib I, Cohen N, Nakhoul F (2003) A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int 64:156–162

93. Estevez R, Boettger T, Stein V, Birkenhager R, Otto E, Hildebrandt F, Jentsch TJ (2001) Barttin is a Cl- channel betas
subunit crucial for renal Cl- reabsorption and inner ear K+ secretion. Nature 414:558–561

94. Yamamoto M, Akatsu T, Nagase T, Ogata E (2000) Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J Clin Endocrinol Metab 85:4583–4591

Answers
1: e
2: c
3: c
4: b
5: d